Suven Life Sciences wins US patents for NCEs

Suven Life Sciences has announced that the US Patent Office has issued two patents for two new chemical entities (NCEs) for use in the treatment of disorders associated with neurodegenerative diseases. The patents (US 7.718,690 and US 7,78,476) are valid until 2022.

Included in the granted claims of the patents are class of selective 5-HT compounds developed by Suven and under development as therapeutic agents for use in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and schizophrenia.

With the new patents, Suven now has a total of eight granted US patentns on NCEs which are the exclusive intellectual property of the company. The se have been achieved through the internal discovery research efforts and products from these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

"We are very pleased by the grant of these patents to Suven by US Patent office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $30 billion market potential globally," says Venkat Jasti, CEO of Suven.

Suven Life Sciences, a biopharmaceutical company, is focused on discovery, development and commercialisation of novel pharmaceutical products, that are first in class or best in class therapies through the use of GPCR targets.

The company counts 12 internally-discovered therapeutic drug candidates at pre-clinical stage of development. These drugs will find use in conditions such as ADHD, dementia, depression, Huntington`s disease, Parkinson`s disease and obesity.

The company said the global market potential of the category of the two NCEs for with it has US patents is estimated at $30 billion.